Consensus statement on the management of the GH-treated adolescent in the transition to adult care

European Journal of Endocrinology

Volumn 152, Issue 2, 2005, Pages 165-170

  Clayton, Peter E ^f   Cuneo, R C ^a   Juul, A ^b   Monson, J P ^c   Shalet, S M ^d   Tauber, M ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Righospitalet ^*  (Denmark)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e HÔPITAL DES ENFANTS   (France)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; ESTROGEN; FOLLITROPIN; GONADORELIN; GROWTH HORMONE; HYDROCORTISONE; LEVOTHYROXINE; TESTOSTERONE;

ADOLESCENCE; ADOLESCENT; ADRENAL CORTEX INSUFFICIENCY; ADULT; ADULTHOOD; ARTICLE; CANCER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; DIABETES MELLITUS; DISEASE EXACERBATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG INDUSTRY; DYSLIPOPROTEINEMIA; ENDOCRINOLOGY; ESTROGEN THERAPY; EUROPE; GROWTH HORMONE DEFICIENCY; HEALTH CARE PLANNING; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MEDICAL SOCIETY; PATIENT CARE; PEDIATRICS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; SHORT STATURE; SMALL FOR DATE INFANT; UNITED KINGDOM; WORKSHOP;

ADOLESCENT; ADOLESCENT HEALTH SERVICES; ADULT; CONTINUITY OF PATIENT CARE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS;

EID: 14644429790     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01829     Document Type: Article

References (20)

1. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency, Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 379-381.
2. Growth Hormone Research Society, Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. Journal of Clinical Endocrinology and Metabolism 2000 85 3990-3993.
3. Tauber M, Jouret B, Cartault A, Lounis N, Gayrard M, Marcouyeux C, Pienkowski C, Oliver I, Moulin P, Otal P, Joffre F, Arnaud C & Rochiccioli P. Adolescents with partial growth hormone (GH) deficiency develop alterations of body composition after GH discontinuation and require follow-up. Journal of Clinical Endocrinology and Metabolism 2003 88 5101-5106.
4. Johannsson G, Albertsson-Wikland K & Bengtsson BA. Discontinuation of growth hormone (GH) treatment: metabolic effects in GH-deficient and GH-sufficient adolescent patients compared with control subjects. Swedish Study Group for Growth Hormone Treatment in Children. Journal of Clinical Endocrinology and Metabolism 1999 84 4516-4524.
5. Vahl N, Juul A, Jorgensen JO, Orskov H, Skakkebaek NE & Christiansen JS. Continuation of growth hormone (GH) replacement in GH-deficient patients during transition from childhood to adulthood: a two-year placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2000 85 1874-1881.
6. Colao A, Di Somma C, Salerno M, Spinelli L, Orio F & Lombardi G. The cardiovascular risk of GH-deficient adolescents. Journal of Clinical Endocrinology and Metabolism 2002 87 3650-3655.
7. Drake WM, Carroll PV, Maher KT, Metcalfe KA, Camacho-Hubner C, Shaw NJ, Dunger DB, Cheetham TD, Savage MO & Monson JP. The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. Journal of Clinical Endocrinology and Metabolism 2003 88 1658-1663.
8. Shalet SM, Shavrikova E, Cromer M, Child CJ, Keller E, Zapletalova J, Moshang T, Blum WF, Chipman JJ, Quigley CA & Attanasio AF. Effect of growth hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2 year randomized, controlled, dose-ranging study. Journal of Clinical Endocrinology and Metabolism 2003 88 4124-4129.
9. Underwood LE, Attie KM Baptista J & Genentech Collaborative Study Group, Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. Journal of Clinical Endocrinology and Metabolism 2003 88 5273-5280.
10. Kelly JJ, Rajkovic IA, O'Sullivan AJ, Sernia C & Ho KK. Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clinical Endocrinology 1993 39 561-567.
11. Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M & Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. American Journal of Physiology. Endocrinology and Metabolism 2001 281 E1191-E1196.
12. GH Research Society, Critical evaluation of the safety of recombinant human growth hormone administration statement from the Growth Hormone Research Society. Journal of Clinical Endocrinology and Metabolism 2001 86 1868-1870.
13. Attanasio AF, Howell S, Bates PC, Frewer P, Chipman J, Blum WF & Shalet SM. Body composition, IGF-I and IGFBP-3 concentrations as outcome measures in severely GH-deficient (GHD) patients after childhood GH treatment: a comparison with adult onset GHD patients. Journal of Clinical Endocrinology and Metabolism 2002 87 3368-3372.
14. Baroncelli GI, Bertelloni S, Sodini F & Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clinical Endocrinology 2004 60 175-184.
15. Howlett TA. An assessment of optimal hydrocortisone replacement therapy. Clinical Endocrinology 1997 46 263-268.
16. Gelding SV, Taylor NF, Wood PJ, Noonan K, Weaver JU, Wood DF & Monson JP. The effect of growth hormone replacement therapy on cortisol-cortisone interconversion in hypopituitary adults: evidence for growth hormone modulation of extrarenal 11 beta hydroxysteroid dehydrogenase activity. Clinical Endocrinology 1998 48 153-162.
17. Elsheikh M, Dunger DB, Conway GS & Wass JA. Turner's syndrome in adulthood. Endocrine Reviews 2002 23 120-140.
18. Hogler W, Briody J, Moore B, Garnett S, Lu PW & Cowell CT. Importance of estrogen on bone health in Turner syndrome: a cross-sectional and longitudinal study using dual-energy X-ray absorptiometry. Journal of Clinical Endocrinology and Metabolism 2004 89 193-199.
19. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M & Hokken-Koelega A. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. Journal of Clinical Endocrinology and Metabolism 2003 88 3584-3590.
20. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C & Drop SL. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. Journal of Clinical Endocrinology and Metabolism 2003 88 1119-1125.